1. Patients must have an intact evaluable primary tumor or biopsy proven axillary node involvement with at least 1.0 cm smallest dimension based on imaging after neoadjuvant anthracycline-based chemotherapy and prior to initiation of neoadjuvant chemotherapy under this protocol. Baseline measurements and evaluations must be obtained within 4 weeks of registration to the study. All areas of disease should be recorded in order to assess response and uniformity of response to therapy.